Loading clinical trials...
Loading clinical trials...
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
Stanford University
Stanford, California, United States
Start Date
July 1, 2020
Primary Completion Date
December 31, 2023
Completion Date
December 31, 2023
Last Updated
December 20, 2024
61
ACTUAL participants
Ertugliflozin
DRUG
Lead Sponsor
Stanford University
Collaborators
NCT07241390
NCT07051005
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions